Table 5 Identification of well treated and undertreated patients using the diagnostic code-based and clinical measurement-based approach
From: Methods to identify the target population: implications for prescribing quality indicators
| Â | Well treated patients | Undertreated patients | Â | ||
|---|---|---|---|---|---|
Type of approach | proportion detected*, % | N | Proportion detected**, % | N | N of eligible patients per PQI |
PQI-1 Prescription of any antihypertensive medication in hypertensive T2DM patients | 2070 | ||||
Reference method | - | 1687 | - | 383 | Â |
Diagnostic code-based, hypertension | 54 (905/1687) | 905 | 21 (79/383) | 79 | Â |
Measurement-based, SBP ≥140 | 84 (1412/1687) | 1412 | 88 (337/383) | 337 |  |
PQI-2 Prescription of beta blocker in hypertensive T2DM patients with a history of IHD or MI | 251 | ||||
Reference method | - | 159 | - | 92 | Â |
Diagnostic code-based, hypertension | 63 (100/159) | 100 | 60 (55/92) | 55 | Â |
Measurement-based, SBP ≥140 | 79 (125/159) | 125 | 75 (69/92) | 69 |  |
PQI-3 Prescription of metformin in overweight T2DM patients | 1837 | ||||
Reference | - | 1193 | - | 644 | Â |
Diagnostic code-based, overweight or obesity | 12 (139/1193) | 139 | 11 (74/644) | 74 | Â |
Measurement-based, BMI ≥25 | 97 (1154/1193) | 1154 | 95 (613/644) | 613 |  |